BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30137696)

  • 1. The International Transporter Consortium: Summarizing Advances in the Role of Transporters in Drug Development.
    Giacomini KM; Galetin A; Huang SM
    Clin Pharmacol Ther; 2018 Nov; 104(5):766-771. PubMed ID: 30137696
    [No Abstract]   [Full Text] [Related]  

  • 2. Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance.
    Zamek-Gliszczynski MJ; Taub ME; Chothe PP; Chu X; Giacomini KM; Kim RB; Ray AS; Stocker SL; Unadkat JD; Wittwer MB; Xia C; Yee SW; Zhang L; Zhang Y;
    Clin Pharmacol Ther; 2018 Nov; 104(5):890-899. PubMed ID: 30091177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium.
    Chu X; Liao M; Shen H; Yoshida K; Zur AA; Arya V; Galetin A; Giacomini KM; Hanna I; Kusuhara H; Lai Y; Rodrigues D; Sugiyama Y; Zamek-Gliszczynski MJ; Zhang L;
    Clin Pharmacol Ther; 2018 Nov; 104(5):836-864. PubMed ID: 30347454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transporters in Drug Development: Scientific and Regulatory Considerations.
    Zhang L; Huang SM; Reynolds K; Madabushi R; Zineh I
    Clin Pharmacol Ther; 2018 Nov; 104(5):793-796. PubMed ID: 30270426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Modeling of Drug-Transporter Interactions-An International Transporter Consortium Perspective.
    Schlessinger A; Welch MA; van Vlijmen H; Korzekwa K; Swaan PW; Matsson P
    Clin Pharmacol Ther; 2018 Nov; 104(5):818-835. PubMed ID: 29981151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective.
    Kenna JG; Taskar KS; Battista C; Bourdet DL; Brouwer KLR; Brouwer KR; Dai D; Funk C; Hafey MJ; Lai Y; Maher J; Pak YA; Pedersen JM; Polli JW; Rodrigues AD; Watkins PB; Yang K; Yucha RW;
    Clin Pharmacol Ther; 2018 Nov; 104(5):916-932. PubMed ID: 30137645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.
    Evers R; Piquette-Miller M; Polli JW; Russel FGM; Sprowl JA; Tohyama K; Ware JA; de Wildt SN; Xie W; Brouwer KLR;
    Clin Pharmacol Ther; 2018 Nov; 104(5):900-915. PubMed ID: 29756222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies to Reduce Solute Carrier-Mediated Toxicity.
    Hu S; Sprowl JA
    Clin Pharmacol Ther; 2018 Nov; 104(5):799-802. PubMed ID: 30028006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening of Drug-Transporter Interactions in a 3D Microfluidic Renal Proximal Tubule on a Chip.
    Vriend J; Nieskens TTG; Vormann MK; van den Berge BT; van den Heuvel A; Russel FGM; Suter-Dick L; Lanz HL; Vulto P; Masereeuw R; Wilmer MJ
    AAPS J; 2018 Jul; 20(5):87. PubMed ID: 30051196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transporters and drug-drug interactions: important determinants of drug disposition and effects.
    König J; Müller F; Fromm MF
    Pharmacol Rev; 2013 Jul; 65(3):944-66. PubMed ID: 23686349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.
    Momper JD; Tsunoda SM; Ma JD
    J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S82-98. PubMed ID: 27385182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
    Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
    Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of Sutherlandia frutescens for herb-drug interaction.
    Fasinu PS; Gutmann H; Schiller H; James AD; Bouic PJ; Rosenkranz B
    Drug Metab Dispos; 2013 Feb; 41(2):488-97. PubMed ID: 23209194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Membrane transporters in drug development.
    ; Giacomini KM; Huang SM; Tweedie DJ; Benet LZ; Brouwer KL; Chu X; Dahlin A; Evers R; Fischer V; Hillgren KM; Hoffmaster KA; Ishikawa T; Keppler D; Kim RB; Lee CA; Niemi M; Polli JW; Sugiyama Y; Swaan PW; Ware JA; Wright SH; Yee SW; Zamek-Gliszczynski MJ; Zhang L
    Nat Rev Drug Discov; 2010 Mar; 9(3):215-36. PubMed ID: 20190787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling approach for multiple transporters-mediated drug-drug interactions in sandwich-cultured human hepatocytes: effect of cyclosporin A on hepatic disposition of mycophenolic acid phenyl-glucuronide.
    Matsunaga N; Suzuki K; Nakanishi T; Ogawa M; Imawaka H; Tamai I
    Drug Metab Pharmacokinet; 2015 Apr; 30(2):142-8. PubMed ID: 25989889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Getting the message across: a recent transporter structure shows the way.
    Henry LK; DeFelice LJ; Blakely RD
    Neuron; 2006 Mar; 49(6):791-6. PubMed ID: 16543127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nephrotoxicity and Kidney Transport Assessment on 3D Perfused Proximal Tubules.
    Vormann MK; Gijzen L; Hutter S; Boot L; Nicolas A; van den Heuvel A; Vriend J; Ng CP; Nieskens TTG; van Duinen V; de Wagenaar B; Masereeuw R; Suter-Dick L; Trietsch SJ; Wilmer M; Joore J; Vulto P; Lanz HL
    AAPS J; 2018 Aug; 20(5):90. PubMed ID: 30109442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of the dominant role of transporters in drug uptake by cells.
    Dobson PD; Lanthaler K; Oliver SG; Kell DB
    Curr Top Med Chem; 2009; 9(2):163-81. PubMed ID: 19200003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the amine-polyamine-choline transporter superfamily 'consensus amphipathic region' as the target for inactivation of the Escherichia coli GABA transporter GabP by thiol modification reagents. Role of Cys-300 in restoring thiol sensitivity to Gabp lacking Cys.
    Hu LA; King SC
    Biochem J; 1999 May; 339 ( Pt 3)(Pt 3):649-55. PubMed ID: 10215604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transporter oligomerization: form and function.
    Alguel Y; Cameron AD; Diallinas G; Byrne B
    Biochem Soc Trans; 2016 Dec; 44(6):1737-1744. PubMed ID: 27913684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.